Holen Sie sich die Stockscreener-App
49.54
0.43%
0.21
Handel nachbörslich:
49.99
0.45
+0.91%
Schlusskurs vom Vortag:
$49.33
Offen:
$48.98
24-Stunden-Volumen:
2.43M
Relative Volume:
0.98
Marktkapitalisierung:
$9.17B
Einnahmen:
$2.69B
Nettoeinkommen (Verlust:
$-214.04M
KGV:
-31.24
EPS:
-1.5857
Netto-Cashflow:
$98.43M
1W Leistung:
-3.49%
1M Leistung:
-31.13%
6M Leistung:
-1.67%
1J Leistung:
-25.28%
1-Tages-Spanne:
$48.82
$50.00
1-Wochen-Bereich:
$48.02
$52.32
52-Wochen-Spanne:
$40.62
$79.62
Exact Sciences Corp Stock (EXAS) Company Profile
Firmenname
Exact Sciences Corp
Sektor
Branche
Telefon
608-284-5700
Adresse
5505 ENDEAVOR LANE, MADISON, WI
Vergleichen Sie EXAS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| EXAS | 49.54 | 9.17B | 2.69B | -214.04M | 98.43M | -1.5857 |
| TMO | 501.29 | 192.46B | 42.37B | 6.14B | 7.78B | 15.26 |
| DHR | 230.06 | 166.23B | 23.74B | 3.89B | 4.98B | 7.93 |
| A | 126.92 | 36.47B | 6.50B | 1.41B | 1.42B | 3.82 |
| IQV | 191.04 | 34.67B | 15.32B | 1.41B | 1.96B | 5.95 |
| IDXX | 419.83 | 34.38B | 3.84B | 866.24M | 792.60M | 9.80 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-01-02 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-10 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-08-02 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Hochstufung | Craig Hallum | Hold → Buy |
| 2023-05-05 | Eingeleitet | UBS | Neutral |
| 2023-03-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-02-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2021-11-03 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Bestätigt | BTIG Research | Buy |
| 2021-07-29 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-29 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-29 | Bestätigt | Stifel | Buy |
| 2021-06-15 | Eingeleitet | Raymond James | Strong Buy |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-10-29 | Herabstufung | UBS | Buy → Neutral |
| 2020-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-02 | Eingeleitet | Evercore ISI | Outperform |
| 2020-01-10 | Fortgesetzt | BTIG Research | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Dougherty & Company | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-17 | Bestätigt | BofA/Merrill | Buy |
| 2019-10-01 | Fortgesetzt | Craig Hallum | Buy |
| 2019-09-26 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-26 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-09 | Eingeleitet | UBS | Buy |
| 2018-09-05 | Fortgesetzt | The Benchmark Company | Hold |
| 2018-08-13 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-01-29 | Eingeleitet | Goldman | Neutral |
| 2018-01-08 | Bestätigt | The Benchmark Company | Buy |
| 2017-11-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Herabstufung | BTIG Research | Buy → Neutral |
Alle ansehen
Exact Sciences Corp Aktie (EXAS) Neueste Nachrichten
Exact Sciences Partners with Actor and TV Personality Carlos Ponce to Increase Awareness of Colon Cancer Screening Among Hispanic Community - Business Wire
Exact Sciences Co. (NASDAQ:EXAS) Shares Acquired by Simplify Asset Management Inc. - MarketBeat
Exact Sciences showcases early cancer detection test data at AACR meeting - Clinical Trials Arena
Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy - BioSpace
Capital World Investors Reduces Stake in Exact Sciences Corp - GuruFocus.com
Exact Sciences CEO Kevin Conroy buys $1 million in stock By Investing.com - Investing.com Nigeria
Exact Sciences reports progress in early cancer detection - Investing.com
Exact Sciences reports progress in early cancer detection By Investing.com - Investing.com UK
Exact Sciences CEO Kevin Conroy buys $1 million in stock - Investing.com India
Los Angeles Capital Management LLC Takes Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Corp (EXAS) Stock Price Down 6.11% on Nov 12 - GuruFocus.com
Exact Sciences Co. (NASDAQ:EXAS) Shares Purchased by WCM Investment Management LLC - MarketBeat
Exact Sciences Corporation (EXAS) Rebounded from the Previous Quarter - Yahoo Finance
15,260 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by Lisanti Capital Growth LLC - MarketBeat
Exact Sciences: Cancer Detection Stalwart's Bad Quarter Resets Its Overgrown Market Cap. - Seeking Alpha
Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Principal Financial Group Inc. - MarketBeat
Wellington Management Group LLP Reduces Stake in Exact Sciences Corp - GuruFocus.com
ARK Investment Management LLC Sells 117,043 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Analysts Set Expectations for Exact Sciences Q4 Earnings - MarketBeat
Exact Sciences’ forecast cut shocks analysts - Yahoo Finance
Exact Sciences Corporation (NASDAQ:EXAS) Q3 2024 Earnings Call Transcript - Insider Monkey
Van ECK Associates Corp Sells 17,484 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' Flop - Yahoo! Voices
Exact Sciences: Q3 Sell-Off May Be Unjustified But Long-Term Outlook A Concern (EXAS) - Seeking Alpha
Madison-based Exact Sciences reports Q3 results short of analysts’ expectations - Lake Geneva Regional News
Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount - Yahoo Finance
Piper Sandler maintains Overweight rating on Exact Sciences shares - Investing.com
Exact Sciences stock target cut by Benchmark, retains Buy rating - Investing.com
Exact Sciences (NASDAQ:EXAS) Shares Gap Down on Disappointing Earnings - MarketBeat
Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point - Yahoo Finance
Exact Sciences (NASDAQ:EXAS) Given New $65.00 Price Target at Benchmark - MarketBeat
Craig Hallum Issues Pessimistic Forecast for Exact Sciences (NASDAQ:EXAS) Stock Price - MarketBeat
Exact Sciences Stock Down On Q3 Earnings & Revenue Miss, '24 View Cut - Barchart
Exact Sciences (NASDAQ:EXAS) Price Target Lowered to $67.00 at Robert W. Baird - MarketBeat
Exact Sciences stock target cut, outperform rating on revenue outlook - Investing.com
Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut - Yahoo Finance
Exact Sciences Corp (EXAS) Q3 2024 Earnings Call Highlights: Str - GuruFocus.com
Exact Sciences Corp (EXAS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight - GuruFocus.com
Exact Sciences Reports Strong Q3 Performance and Pipeline Advances - TipRanks
Exact Sciences Announces Third-Quarter 2024 Results - BioSpace
Exact Sciences (EXAS) Q3 2024 Earnings Call Transcript - Yahoo Finance
Exact Sciences (EXAS) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Exact Sciences: Q3 Earnings Snapshot - San Antonio Express-News
EXACT Sciences earnings missed, revenue fell short of estimates - Investing.com
Exact Sciences Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
After-hours movers: Super Micro Computer, Exact Sciences, Trump Media & Technology - Investing.com
Exact Sciences Stock Plummets After Worse-Than-Expected Q3 Results, FY24 Guidance Below Estimates - Benzinga
Exact Sciences Corp Q3 2024 Earnings: Revenue at $709M, EPS at -$0.21, Misses Estimates - GuruFocus.com
Finanzdaten der Exact Sciences Corp-Aktie (EXAS)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.04%
3.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):